Further inhibition of the MAPK pathway through nodes orthogonal to existing MAPK pathway inhibitor targets, such as the SHOC2–PP1C–RAS complex, may help to downregulate ERK signalling more effectively in relevant tumours. Here, SHOC2 is linked to neoplasm.